Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease

Julie R. Gralow, Harold J. Burstein, William Wood, Gabriel N. Hortobagyi, Luca Gianni, Gunter Von Minckwitz, Aman U. Buzdar, Ian E. Smith, William F. Symmans, Baljit Singh, Eric P. Winer

Research output: Contribution to journalArticle

Abstract

Purpose: To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer. Methods: This article reviews data presented at the National Cancer Institute State of the Science Conference on Preoperative Therapy in Invasive Breast Cancer as well as supporting published data. Results: Preoperative chemotherapy in operable breast cancer has been shown to improve breast conservation rates as a result of tumor response to therapy. When patients are given preoperative systemic therapy, regimens should be the same as those established as safe and active in the adjuvant setting. At present, there are no data to suggest that systemic treatment should be tailored based on initial tumor response, or based on the extent of residual disease. In operable breast cancer, there seems to be no survival advantage from initiation of systemic therapy before surgery. A variety of clinical, imaging, and pathologic measurements are available to gauge tumor response to treatment. There is a clear correlation between tumor response in the breast and lymph nodes and both disease-free and overall survival. Pathologic complete response and other pathologic measures may be useful as surrogate end points in evaluating and understanding new therapies. Conclusion: In operable breast cancer, preoperative systemic therapy is effective and can improve breast conservation rates. Unless the tumor is large or the patient is in a clinical trial, postoperative adjuvant systemic therapy is the standard of care. To achieve optimal outcomes, preoperative systemic therapy must be administered as part of a coordinated, multimodality treatment program. The preoperative setting provides a unique opportunity to study the impact of systemic therapies on breast cancer biology.

Original languageEnglish
Pages (from-to)814-819
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number5
DOIs
Publication statusPublished - Feb 2 2008

Fingerprint

Breast Neoplasms
Therapeutics
Breast
Neoplasms
National Cancer Institute (U.S.)
Standard of Care
Disease-Free Survival
Biomarkers
Lymph Nodes
Clinical Trials
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Preoperative therapy in invasive breast cancer : Pathologic assessment and systemic therapy issues in operable disease. / Gralow, Julie R.; Burstein, Harold J.; Wood, William; Hortobagyi, Gabriel N.; Gianni, Luca; Von Minckwitz, Gunter; Buzdar, Aman U.; Smith, Ian E.; Symmans, William F.; Singh, Baljit; Winer, Eric P.

In: Journal of Clinical Oncology, Vol. 26, No. 5, 02.02.2008, p. 814-819.

Research output: Contribution to journalArticle

Gralow, JR, Burstein, HJ, Wood, W, Hortobagyi, GN, Gianni, L, Von Minckwitz, G, Buzdar, AU, Smith, IE, Symmans, WF, Singh, B & Winer, EP 2008, 'Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease', Journal of Clinical Oncology, vol. 26, no. 5, pp. 814-819. https://doi.org/10.1200/JCO.2007.15.3510
Gralow, Julie R. ; Burstein, Harold J. ; Wood, William ; Hortobagyi, Gabriel N. ; Gianni, Luca ; Von Minckwitz, Gunter ; Buzdar, Aman U. ; Smith, Ian E. ; Symmans, William F. ; Singh, Baljit ; Winer, Eric P. / Preoperative therapy in invasive breast cancer : Pathologic assessment and systemic therapy issues in operable disease. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 5. pp. 814-819.
@article{23b819b30f8449e188abc35b8891373f,
title = "Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease",
abstract = "Purpose: To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer. Methods: This article reviews data presented at the National Cancer Institute State of the Science Conference on Preoperative Therapy in Invasive Breast Cancer as well as supporting published data. Results: Preoperative chemotherapy in operable breast cancer has been shown to improve breast conservation rates as a result of tumor response to therapy. When patients are given preoperative systemic therapy, regimens should be the same as those established as safe and active in the adjuvant setting. At present, there are no data to suggest that systemic treatment should be tailored based on initial tumor response, or based on the extent of residual disease. In operable breast cancer, there seems to be no survival advantage from initiation of systemic therapy before surgery. A variety of clinical, imaging, and pathologic measurements are available to gauge tumor response to treatment. There is a clear correlation between tumor response in the breast and lymph nodes and both disease-free and overall survival. Pathologic complete response and other pathologic measures may be useful as surrogate end points in evaluating and understanding new therapies. Conclusion: In operable breast cancer, preoperative systemic therapy is effective and can improve breast conservation rates. Unless the tumor is large or the patient is in a clinical trial, postoperative adjuvant systemic therapy is the standard of care. To achieve optimal outcomes, preoperative systemic therapy must be administered as part of a coordinated, multimodality treatment program. The preoperative setting provides a unique opportunity to study the impact of systemic therapies on breast cancer biology.",
author = "Gralow, {Julie R.} and Burstein, {Harold J.} and William Wood and Hortobagyi, {Gabriel N.} and Luca Gianni and {Von Minckwitz}, Gunter and Buzdar, {Aman U.} and Smith, {Ian E.} and Symmans, {William F.} and Baljit Singh and Winer, {Eric P.}",
year = "2008",
month = "2",
day = "2",
doi = "10.1200/JCO.2007.15.3510",
language = "English",
volume = "26",
pages = "814--819",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Preoperative therapy in invasive breast cancer

T2 - Pathologic assessment and systemic therapy issues in operable disease

AU - Gralow, Julie R.

AU - Burstein, Harold J.

AU - Wood, William

AU - Hortobagyi, Gabriel N.

AU - Gianni, Luca

AU - Von Minckwitz, Gunter

AU - Buzdar, Aman U.

AU - Smith, Ian E.

AU - Symmans, William F.

AU - Singh, Baljit

AU - Winer, Eric P.

PY - 2008/2/2

Y1 - 2008/2/2

N2 - Purpose: To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer. Methods: This article reviews data presented at the National Cancer Institute State of the Science Conference on Preoperative Therapy in Invasive Breast Cancer as well as supporting published data. Results: Preoperative chemotherapy in operable breast cancer has been shown to improve breast conservation rates as a result of tumor response to therapy. When patients are given preoperative systemic therapy, regimens should be the same as those established as safe and active in the adjuvant setting. At present, there are no data to suggest that systemic treatment should be tailored based on initial tumor response, or based on the extent of residual disease. In operable breast cancer, there seems to be no survival advantage from initiation of systemic therapy before surgery. A variety of clinical, imaging, and pathologic measurements are available to gauge tumor response to treatment. There is a clear correlation between tumor response in the breast and lymph nodes and both disease-free and overall survival. Pathologic complete response and other pathologic measures may be useful as surrogate end points in evaluating and understanding new therapies. Conclusion: In operable breast cancer, preoperative systemic therapy is effective and can improve breast conservation rates. Unless the tumor is large or the patient is in a clinical trial, postoperative adjuvant systemic therapy is the standard of care. To achieve optimal outcomes, preoperative systemic therapy must be administered as part of a coordinated, multimodality treatment program. The preoperative setting provides a unique opportunity to study the impact of systemic therapies on breast cancer biology.

AB - Purpose: To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer. Methods: This article reviews data presented at the National Cancer Institute State of the Science Conference on Preoperative Therapy in Invasive Breast Cancer as well as supporting published data. Results: Preoperative chemotherapy in operable breast cancer has been shown to improve breast conservation rates as a result of tumor response to therapy. When patients are given preoperative systemic therapy, regimens should be the same as those established as safe and active in the adjuvant setting. At present, there are no data to suggest that systemic treatment should be tailored based on initial tumor response, or based on the extent of residual disease. In operable breast cancer, there seems to be no survival advantage from initiation of systemic therapy before surgery. A variety of clinical, imaging, and pathologic measurements are available to gauge tumor response to treatment. There is a clear correlation between tumor response in the breast and lymph nodes and both disease-free and overall survival. Pathologic complete response and other pathologic measures may be useful as surrogate end points in evaluating and understanding new therapies. Conclusion: In operable breast cancer, preoperative systemic therapy is effective and can improve breast conservation rates. Unless the tumor is large or the patient is in a clinical trial, postoperative adjuvant systemic therapy is the standard of care. To achieve optimal outcomes, preoperative systemic therapy must be administered as part of a coordinated, multimodality treatment program. The preoperative setting provides a unique opportunity to study the impact of systemic therapies on breast cancer biology.

UR - http://www.scopus.com/inward/record.url?scp=39149083784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149083784&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.3510

DO - 10.1200/JCO.2007.15.3510

M3 - Article

C2 - 18258991

AN - SCOPUS:39149083784

VL - 26

SP - 814

EP - 819

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -